The IVW method was used to analyze GLGC data, which indicated that HMGCR inhibitor (HMGCRi), PCSK9 inhibitor (PCSK9i), and NPC1L1 inhibitor (NPC1L1i) have a significant potential to reduce the risk of CHD (OR [95%] = 0.7679 [0.5629, 0.9729], p = 1.16 × 10−2; OR [95%] = 0.7952 [0.5711, 1.0194], p = 4.52 × 10−2; OR [95%] = 0.6359[0.2335, 1.0384], p = 2.75 × 10−2) (as shown in Figure 2). This evidence concerns the gene PCSK9 and coronary artery disorder.